Figure 2.
Multivariate analysis of transplant outcomes comparing 7/8 CNI/MTX/abatacept to 8/8 CNI/MTX/placebo. Forest plot depicting the results of multivariate analysis with adjusted hazard ratio (HR; diamonds, with 95% CIs shown with bars) comparing 7/8 MMUD with CNI/MTX/abatacept to 8/8 MUD with CNI/MTX/placebo. In this Forest plot, the adjusted HR uses 8/8 CNI/MTX/placebo as baseline, with HR <1.0 being favorable for the 7/8 CNI/MTX/abatacept group. This multivariate analysis controlled for age, performance score, disease stage, graft type, and conditioning regimen. Shown are adjusted HR for relapse, TRM, RFS, OS, GVHD-free-relapse-free survival (using the modified GFRS definition, with severe aGVHD, moderate-to-severe chronic GVHD, relapse, and death considered as events), and SGFS.

Multivariate analysis of transplant outcomes comparing 7/8 CNI/MTX/abatacept to 8/8 CNI/MTX/placebo. Forest plot depicting the results of multivariate analysis with adjusted hazard ratio (HR; diamonds, with 95% CIs shown with bars) comparing 7/8 MMUD with CNI/MTX/abatacept to 8/8 MUD with CNI/MTX/placebo. In this Forest plot, the adjusted HR uses 8/8 CNI/MTX/placebo as baseline, with HR <1.0 being favorable for the 7/8 CNI/MTX/abatacept group. This multivariate analysis controlled for age, performance score, disease stage, graft type, and conditioning regimen. Shown are adjusted HR for relapse, TRM, RFS, OS, GVHD-free-relapse-free survival (using the modified GFRS definition, with severe aGVHD, moderate-to-severe chronic GVHD, relapse, and death considered as events), and SGFS.

Close Modal

or Create an Account

Close Modal
Close Modal